
ADVANCING MOLECULAR DIAGNOSTICS TO THE POINT-OF-CARE

21 November 2022

Year End Results: Jun-22





DOCUMENT INFORMATION

NOT FOR PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. This document, which comprises a presentation of the results for the period ending 31 December 2021, has been prepared by genedrive PLC ("genedrive"). By reviewing this presentation you agree to be bound by the following conditions. The release, presentation, publication or distribution of this presentation, in whole or in part, in certain jurisdictions may be restricted by law or regulation and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions.

No representation or warranty (express or implied) of any nature is given nor is any responsibility or liability of any kind accepted by genedrive or any of its directors, officers, employees, advisers, representatives or other agents, with respect to the truthfulness, completeness or accuracy of any information, projection, representation or warranty (express or implied), omissions, errors or misstatements in this presentation, or any other written or oral statement provided. None of genedrive or its affiliates, advisors or representatives shall have any liability whatsoever (in negligence or otherwise) for any loss howsoever arising from any use of this material or otherwise in connection with this material.

Nothing contained in this presentation is intended to constitute an invitation or inducement to engage in investment activity for the purposes of the prohibition on financial promotions in section 21 of the UK Financial Services and Markets Act 2000. In making this presentation available, genedrive makes no recommendation to buy, sell or otherwise deal in shares of genedrive or in any other securities or investments whatsoever and does not constitute or form part of any offer, or an invitation to sell or issue or subscribe for or purchase any securities in nor of genedrive and you should neither rely nor act upon, directly or indirectly, any of the information contained in this presentation in respect of any such investment activity. Further, it should not be treated as giving investment, legal, accounting, regulatory, taxation or other advice.

Any recipients of this presentation outside the UK should inform themselves of and observe any applicable legal or regulatory requirements in their jurisdiction, and are treated as having represented that they are able to receive this presentation without contravention of any law or regulation in the jurisdiction in which they reside or conduct business. In particular, the securities referred to in this presentation have not been and will not be registered under the U.S. Securities Act of 1933 and may not be offered, sold or transferred within the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act of 1933.

This presentation includes statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believes", "estimates", "anticipates", "expects", "intends", "plans", "goal", "target", "aim", "may", "will", "would", "could" or "should" or, in each case, their negative or other variations or comparable terminology. These forward-looking statements include all matters that are not historical facts. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future and may be beyond genedrive's ability to control or predict, and future events and circumstances can cause results and developments to differ materially from those anticipated. Nothing in this presentation should be construed as a profit forecast. Forward-looking statements are not guarantees of future performance and hence may prove to be erroneous. Other than in accordance with its legal or regulatory obligations (including under the AIM Rules for Companies, Market Abuse Regulation and the Disclosure Guidance and Transparency Rules), genedrive does not undertake any obligation to update or revise publicly any forward-looking statement, whether as a result of new information, future events or otherwise.

This presentation has been prepared without reference to your particular investment objectives, financial situation, taxation position and particular needs. It is important that you view this presentation in its entirety. If you are in any doubt in relation to these matters, you should consult your stockbroker, bank manager, solicitor, accountant, taxation adviser or other independent financial adviser (where applicable, as authorised under the Financial Services and Markets Act 2000).


genedrive

CAPABILITIES OVERVIEW









GENEDRIVE TECHNOLOGY

genedrive

- ✓ **Rapid** Point-of-care or Decentralised location testing
- Patented amplification technology.
- Two low-cost platform options (1) single button menu (& android app) or (2) integrated touchscreen system.
- Total Analysis Time: 7.5 90 minutes depending on target and amplification chemistry.

✓ **Easy of Use** by those with no previous molecular diagnostic experience

- Solid-state components, no field repair.
- Single use disposable freeze dried assays no complex reagent preparation.
- Closed system for specific clinical applications.
- Assay specific software.

✓ Versatile Test Menu

- Existing tech developed for HCV, COVID19, MT-RNR1, Military Pathogens.
- Supports a variety of amplification technologies (PCR, RT-PCR, LAMP, RT-LAMP, realtime or end-point detection and discrimination of DNA or RNA targets).

STRATEGY - GENETIC INFORMATION FOR URGENT TREATMENT CHALLENGES

- genedrive has a solid track record for innovation.
- Increasingly focused on acute medicine / pharmacogenetics where rapid genetic information can help tailor emergency medical care.
- In 2022, genedrive was the first company to deploy a commercial point-of-care genetic test (Genedrive® MT-RNR1 ID Kit) into an emergency care setting.
- In development is our 1-hour Genedrive® CYP2C19 assay that can be used across a broad range of indications.
- Portfolio of other tests, including a direct from plasma confirmation of HCV infection test and a rapid 7.5 min point-of-care test for COVID-19 detection.





OPERATIONAL HIGHLIGHTS (FY AND ONWARDS)


- JAMA Pediatrics' PALOH (Pharmacogenetics to Avoid Loss of Hearing) paper published.
- Launched 2nd generation Genedrive® system to support strategy focus of pharmacogenomics into emergency care settings.
- First sales for Genedrive MT-RNR1.
- **First deployments** of the Genedrive® System for Antibiotic Induced Hearing Loss at Manchester Royal Infirmary (St Mary's) & subsequent routine clinical use.
- New **CYP2C19 product development** programme initiated for use of Genedrive® Point-of-Care device for ischemic stroke treatment in emergency care settings.
- NICE accelerated evaluation of the Genedrive® MT-RNR1 ID test to Q1 2023.
- NICE includes Genedrive® CYP2C19 ID Kit in Diagnostics Assessment Programme.
- Point-of-Care Genedrive® COV19-ID Kit received Coronavirus Test Device Approval ("CTDA").
- Filed **US FDA Pre-submission** for the Genedrive® MT-RNR1 ID product range.



COMMERCIAL HIGHLIGHTS (FY AND ONWARDS)

- New Commercial Sales team recruited since mid-year
 - RNR1 Commercial Sales in UK and Supporting
 Inspiration Healthcare activities
 - Diligence and Contracting/Onboarding new MT-RNR1 partners internationally, with a primary focus on Europe
 - Pursuing COVID-19 opportunities in selected countries if opportunity presents
- New Commercial Marketing Team established
 - Managing and driving NICE processes
 - Supporting NHS Trust through their business case process to get funding into place, prior to national commissioning and NICE recommendations
 - Engagement of the market to raise awareness on Genedrive MT-RNR1.
 - Over 2 dozen independent publications on Genedrive innovations since January

COMMERCIAL ONBOARDING





bables with suspected sepils, who need treatment as fast as possible. About one in 500 people have a genetic mutation that means that the antibiotic gentamicin kills cells inside their ear. This is thought to cause about 14.000 people worldwide to go permanently deaf each


CLINICAL MARKET AWARENESS





Antibiotic Induced Hearing Loss (AIHL)

Genedrive MT-RNR1 ID Kit



Pioneering PALOH study using Genedrive MT-RNR1 ID Kit

JAMA Pediatrics | Original Investigation

Rapid Point-of-Care Genotyping to Avoid Aminoglycoside-Induced Ototoxicity in Neonatal Intensive Care

John H. McDermott, MD, MRes; Ajit Mahaveer, MD; Rachel A. James, PhD; Nicola Booth, RN, PhD; Mark Turner, MD, PhD; Karen E. Harvey, RN; Gino Miele, PhD; Glenda M. Beaman, PhD; Duncan C. Stoddard, MSc; Karen Tricker, PhD; Rachel J. Corry, MSc; Julia Garlick, MSc; Shaun Ainsworth, PhD; Thomas Beevers, BSc; Iain A. Bruce, MD, PhD; Richard Body, MD, PhD; Fiona Ulph, PhD; Rhona MacLeod, PhD; Peter L. Roberts, BA; Paul M. Wilson, BA; William G. Newman, MD, PhD; for the PALOH Study Team

- 26-minute test, described as "entering a new era", and "an important step" in the management of neonatal sepsis
- No disruption to clinical pathway by using test.
- 3 babies identified as having the MT-RNR1 1555A>G variant, and alternative antibiotic given to avoid lifelong hearing loss.





AIHL – GENEDRIVE MT-RNR1 ID KIT

Genedrive[®] MT-RNR1 ID Kit

- Ototoxicity from antibiotics is a widely known issue with specific clinical guidance (CPIC) on genetic mutations
- High unmet need, with an addressable market globally >£100m
- Provides an automated result of an individual's MT RNR1 m.1555 genetic variant status to inform the clinician ahead of antibiotic treatment decisions
- Manchester St Mary's adopted and live, 2* more expected on stream shortly and 8* more clusters in the sales funnel. (*Subject to contracts)
- High enthusiasm for adoption by NHS front line staff
- Inspiration Healthcare appointed as the UK distributor Spain also now contracted and 3 other countries imminent
- Currently subject to NICE accelerated Early Value Assessment

High unmet need 100k UK 1/500 Addressable Market >£100m **CE Marked** Sensitivity 100% Specificity 99.2% Positive **Health Economics** NICE FDA PALOH



MT-RNR1

AIHL – GENEDRIVE MT-RNR1 ID KIT

Health Economics


- Significant unmet need globally, with no direct competition currently
- Clinician interest level is encouraging
- National commissioning process
- NICE review/recommendation
- Supporting Individual Trusts with Business Cases through the buying process with Independently validated Health Economic Outcome Model
- Demonstrating the cost benefits of running Genedrive vs avoided costs of Cochlear implants

Health Economic Model

Unit population (To be entered by user)			1,500				
			%	No. Patients		tely 1:500 (0.2%)	
Potential patients receiving aminoglycoside antibiotics			100%	1500		in the mitochon	
Population with mutation in the mitochondrial genome (m.1555A>G)		G)	0.20%	3.0		, which is highly	
	-					ateral irreversib even after a sin	
Genedr	ive Product (Costs			nearing loss	Gentamicin.	gie exposure i
			Frequency Total Annual		(Prezant et al 1993; Bitner-Glindzicz et al. 200		
		Cost Price	per patient	Cost	(Freedorie et al	1990, bittier om	TOLICE CE ON LO
MT-RNR1 ID Kits for Patient Tests (single test)		£85.00	1.00	£127,500.00			
		Cost Price	Number of	Total Annual			
		Cost Price	Systems	Cost		Cells	
Gendrive System (GS-002) Minimum 2 per NICU		£4,999.00	6	£29,994.00		Highlighted in	
Gendrive System (GS-002) Warranty annual charge				£0.00		yellow can be	•
Frequency of Genedrive System (GS-002) replacement (Years)		8			changed		
		Cost Price	Frequency	Total Annual			
		Cost Price	per month	Cost			
MT-RNR1 ID Kit for Quality Control (2 tests per System monthly)		£85.00	2.00	£12,240.00			
MT-RNR1 Control Kit (2 test per System monthly)		£35.00	2.00	£5,040.00			
Total annual Genedrive product costs		1st Year £174,774.00		£174,774.00			
		Recurre	nt Years £144,780.00				
		Net Financia	I Impact				
	1st Year	2nd Year	3rd Year	4th Year	5th Year	6th Year	7th Year
Cost of Implementing Genedrive System	£174,774.00	£144,780.00	£144,780.00	£144,780.00	£144,780.00	£144,780.00	£144,780.00
Avoided costs of bilateral cochlear implants	£180,848	£183,274	£185,700	£188,127	£190,553	£192,979	£195,405
	2100,010	2200,274	2100,700	2100,127	2200,000	2202,070	2200,100
	£6,074	£44,567	£85,488	£128,834	£174,607	£222,806	£273,432
Cumulative Net Savings							



Genedrive[®] **CYP2C19-ID** Kit




- Genedrive's AIHL clearly demonstrates opportunities in the evolving point of need pharmacogenetics market
- Drugs such as Clopidogrel can prevent further strokes or cardiac events can be highly effective, or not effective at all in some individuals depending on their CYP2C19 gene.
- Very large opportunities for example, over 32 million antiplatelet items were prescribed in 2020/21 at a total cost to the NHS of over £78m.
- USA market has high value and established reimbursement (Medicare CPT Code 81225, circa \$291)
- NICE has now included Genedrive's CYP2C19-ID Kit in new Diagnostics Assessment Programme
- Looking to country specific distribution partners where CYP2C19 clinical guidelines are applicable

Cono						
A new easy t	C19 ID Kit* to use molecular point of care test for rapid notyping for emergency care settings.					
genotypes to infor	YP2C19 ID Kit will provide a rapid, automated result of targeted CYP2C19 m clinicians on metaboliser status ahead of treatment strategies using drugs ad by Cytochrome P450 2C19 (CYP2C19).					
effective and avoid	testing assists prescribers to select tailored treatment and doses that are most d those which may cause adverse reactions in an individual with a known is facilitates effective prescription in a clinically relevant timeframe, thereby putcomes.					
Clopidogrel is a prodrug, requiring conversion by the enzyme CYP2C19 and is administered for the management of ischaemic strokes.						
	es which define CYP2C19 metaboliser status are well described and dosing have been produced by the Clinical Pharmacogenetics Implementation					
	R					
Speed	Rapid results in less than one hour for use in urgent care settings					
Simple to use	Point of care test performed by healthcare professionals					
Ready to use	Ambient temperature-stable reagents, negating the requirement for cold chain storage, for immediate use					
Non-Invasive	Test performed using a single buccal swab sample from the inner cheek					
Comprehensive	mprohensive Broad variant coverage identifying clinically relevant alleles of CYP2C19 including *2, *3, *4, *8, *17 and *35					
au montivet in comments in development a	nd does not have consistent amount with find modifications a black to choose - wellability 2022					

Them product in currently in development and does not have regulatory approval, with their spectrations subject to cr 1 Lee C.R. et al 2022 CPIC Guideline for CYP2CI9 Genotype and Clopidogrei Therapy: 2022 Update



13



ive

- Product currently entering Verification and Validation phase
- Targeting a UK launch date March/April 2023
- Will be subject to new IVDR regulation for
- Commercial Team doing due diligence on commercial partners

IPC

55 60 65

Temperature *C

14




Genedrive[®] COV19-ID kit



PRODUCT: GENEDRIVE® SARS COV-2 ID KIT

- CE marked in December 2021 and CTDA approval in May-22
- 7.5-17 minute test time = faster than competitive systems
- No viral extraction = avoids complexity
- Simple workflow (similar to lateral flow antigen test procedure)
- Launched after the last meaningful wave of COVID infection
- Testing has not yet returned (actively being discouraged) but we are able address any uptick should market demand change



(+) as little as 7.5 minutes





Summary Financials

.

SUMMARY FINANCIALS

Income statement	FY22 £'000	FY21 £'000
Revenue	49	687
Operating costs	(5,664)	(6,169)
Operating loss	(5,615)	(5,482)
Finance (costs)/income	(16)	3,630
Loss before tax	(5,631)	(1,852)
Тах	956	1,161
Loss after tax	(4,675)	(691)
	5)(00	51/04
Cashflow	FY22	FY21
	£'000	£'000
Cashflow from operations	(5,327)	(5,237)
Working capital	(433)	(933)
Taxation	1,166	1,018
Other	(85)	(180)
Net cashflow from operations	(4,679)	(5,332)
		()
Settlement of convertibles	-	(358)
Proceeds from share issue	6,694	46
	0.045	(5.044)
Net cash flow	2,015	(5,644)
Cash at bank b/f	2,574	8,218
Cash at bank c/f	4,589	2,574
	1,000	_,•••
Underlying monthly burn rate:	FY22	FY21
	£'000	£'000
Gross	(487)	(529)
Adjusted for taxation	(390)	(444)
	(000)	()



Income statement

- Operating costs reduced by £0.5m due to sales activity and tight cost control
- Settlement of last convertible Loan Notes generated finance income, contributing to £3.6m income in FY21

Cashflow

- Cash consumption from operations is £5.3m similar to FY21
- Working capital consumed £0.4m £0.5m less than FY21 due to reduction in creditors
- £1.2m receipt from HMRC R&D tax credit scheme
- Final convertible loan notes settled £0.4m outflow in FY21
- Fund raise of £6.6m net in October 2021
- Unaudited cash at 31 October 2022 of £3.0m
- Underlying cash consumption of £487k per month
- Adjusting for R&D tax credit received monthly rate reduces to £390k

ANTICIPATED NEWS FLOW

<6 Months

- Sign up and contracting of additional distribution partners for MT-RNR1
- Additional go-live sites in the UK for Genedrive MT RNR1
- Completion consultation of NICE review for Genedrive MT RNR1
- Promotion and launch of Genedrive MTRNR1 assay in other EU countries
- Launch of CYP2C19 in the UK (UKCA mark)

>6 Months

- Completion of NICE review for Genedrive CYP2C19
- Launch of CYP2C19 in other territories following IVDR registration
- Begin FDA registration processes pending positive pre-sub process and funding



genedrive

Thank you.

